In adult patients with relapsed or refractory (R/R) mantle cell lymphoma
TECARTUS® provided deep and durable responses1
Primary analysis: In ZUMA-2, nearly all patients achieved a response (n=52/60) with TECARTUS at a median study follow-up of 12.3 months1,2
Pinch to zoom
Leukapheresis to complete remission in <4 months3*
- Median time from infusion to complete response: 3.0 months (range: 1.0, 9.3)4
Consistent response rates achieved across efficacy analyses
Response rates in
ZUMA-2
Efficacy-evaluable population (n=60)
Primary analysis1,2
(data cutoff July 24, 2019)
Response rate (n) [95% Cl]
Objective response rate
87% (52) [75, 94]
Complete response rate
62% (37) [48, 74]
Partial response rate
25% (15) [15, 38]
~3-year analysis5
(data cutoff July 24, 2021)
Response rate (n) [95% Cl]
Objective response rate
87% (52) [75, 94]
Complete response rate
63% (38) [50, 75]
Partial response rate
23% (14) [13, 36]
All leukapheresed patients (n=74)
Primary analysis1,2
(data cutoff July 24, 2019)
Response rate (n) [95% Cl]
Objective response rate
80% (59) [69, 88]
Complete response rate
55% (41) [43, 67]
Partial response rate
24% (18) [15, 36]
~3-year analysis6
(data cutoff July 24, 2021)
Response rate (n) [95% Cl]
Objective response rate
80% (59) [69, 88]
Complete response rate
57% (42) [45, 68]
Partial response rate
23% (17) [14, 34]
Efficacy-evaluable population (n=60)
Response rate (n) [95% Cl]
Primary analysis1,2
(data cutoff July 24, 2019)
~3-year analysis5
(data cutoff July 24, 2021)
Objective response rate
Complete response rate
Partial response rate
87% (52) [75, 94]
62% (37) [48, 74]
25% (15) [15, 38]
87% (52) [75, 94]
63% (38) [50, 75]
23% (14) [13, 36]
All leukapheresed patients (n=74)
Response rate (n) [95% Cl]
Primary analysis1,2
(data cutoff July 24, 2019)
~3-year analysis6
(data cutoff July 24, 2021)
Objective response rate
Complete response rate
Partial response rate
80% (59) [69, 88]
55% (41) [43, 67]
24% (18) [15, 36]
80% (59) [69, 88]
57% (42) [45, 68]
23% (17) [14, 34]
*Median: 3.9 months (range: 1.6, 10.2).3
CI=confidence interval; CR=complete response; DOR=duration of response; MCL=mantle cell lymphoma; ORR=objective response rate; PR=partial response; R/R=relapsed or refractory.
References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 3. Data on file. Kite Pharma, Inc; 2023. 4. Data on file. Kite Pharma, Inc; 2019. 5. Data on file [1]. Kite Pharma, Inc; 2022. 6. Data on file [2]. Kite Pharma, Inc; 2022.
TECARTUS provided 36.5 months mDOR, at ~3 years median study follow-up2,3*†
Tick marks represent censored patients. Subjects not meeting the criteria (ie, patients who experienced disease progression or death) by the analysis data cutoff date were censored at their last evaluable disease assessment date prior to the data cutoff date or new anticancer therapy (including SCT) start date, whichever was earlier.3
Pinch to zoom
- DOR was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study4
- DOR data from the ~3-year analysis are not included in the USPI. DOR data are descriptive and should be carefully interpreted
- ~3-year median follow-up analysis was conducted after all 68 patients treated with TECARTUS in the ZUMA-2 study had the opportunity to be followed for at least 24 months5
- In the primary analysis, mDOR was not reached (95% CI: 8.6, NE) in both the efficacy-evaluable population (n=52) and the all leukapheresed population (n=59) at a median study follow-up of 12.3 months1,4
*Kaplan-Meier estimate based on the 52 patients with a response. Median duration of study follow-up was 35.6 months.2,3
†DOR was measured from the start of first objective response to the date of progression or death.1
CI=confidence interval; CR=complete response; DOR=duration of response; mDOR=median duration of response; NE=not estimable; OR=overall response; ORR=objective response rate; PR=partial response; SCT=stem cell transplant; USPI=US Prescribing Information.
References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file [1]. Kite Pharma, Inc; 2022. 3. Data on file [2]. Kite Pharma, Inc; 2022. 4. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 5. Data on file [3]. Kite Pharma, Inc; 2022.